Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD64 CAR-T cells |
| Synonyms | |
| Therapy Description |
CD64 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting FCGR1A (CD64), which potentially inhibit tumor growth (Blood (2024) 144 (Supplement 1): 702). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD64 CAR-T cells | CD64 CAR T-cells|CD64 CAR T cells | CD64 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting FCGR1A (CD64), which potentially inhibit tumor growth (Blood (2024) 144 (Supplement 1): 702). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07347418 | Phase I | CD64 CAR-T cells | CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS | Not yet recruiting | USA | 0 |